Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2008-09-22
2010-12-21
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C424S520000, C514S002600
Reexamination Certificate
active
07855174
ABSTRACT:
The invention encompasses methods of decreasing the lumenal diameter of a blood vessel by contacting the vessel with a myosin light chain phosphatase inhibitor.
REFERENCES:
Landry et al.The pathogenesis of vasodilatory shock. N Eng J Med. 2001; 345(8):588-595.
Li J et al. Peroxynitrite-induced relaxation in isolated rat aortic rings and mechanisms of action. Toxicol Appl Pharmacol. 2005; 209:269-276.
Li W et al. Cocaine-induced relaxation of isolated rat aortic rings and mechanisms of action: possible relation to cocaine-induced aortic dissection and hypotension. Eur J Pharmacol. 2004; 496:151-158.
Xu et al. The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic shock in the rat. Shock, 2005; 23(6):576-581.
Bolz S et al. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation, 2003; 107:3081-3087.
Liu H-P et al. Myosin phosphatase inhibiton restores catecholamine sensitivity in vasodilatory shock. (Meeting Abstract) Anesthesiology, Oct. 15, 2007; 107:A1320.
Zhao K-S et al. New approach to treatment of shock—restitution of vasoreactivity. Shock, 2002; 18(2):189-192.
Abderrahmane, A., et al., “The Large Conductance, Voltage-dependent, and Calcium-sensitive K+ Channel, Hslo, Is a Target of cGMP-dependent Protein Kinase Phosphorylation in Vivo,” The Journal of Biological Chemistry, Dec. 4, 1998, pp. 32950-32956, vol. 273, No. 49.
“Part 6: Advanced Cardiovascular Life Support, Section 6: Pharmacology II: Agents to Optimize Cardiac Output and Blood Pressure,” Resuscitation, 2002, pp. 155-162, vol. 46.
Benedict, C., et al., “Arterial Norepinephrine Changes in Patients with Septic Shock,” Circulatory Shock, 1992, pp. 165-172, vol. 38.
Boyle, W., et al., “iNOS Gene Expression Modulates Microvascular Responsiveness in Endotoxin-challenged Mice,” Circulation Research, Sep. 29, 2000, pp. 1-7.
Chernow, B., et al., “Pharmacologic Manipulation of the Peripheral Vasculature in Shock: Clinical and Experimental Approaches,” Circulatory Shock, 1986, pp. 141-155, vol. 18.
Cobb, J., “Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red,” Critical Care Medicine, 1999, pp. 855-856, vol. 27, No. 5.
Dimopoulos, G., et al., “Ca2+-Dependent Rapid Ca2+ Sensitization of Contraction in Arterial Smooth Muscle,” Circulation Research, Jan. 5-19, 2007, pp. 121-129.
Dünser, M., et al., “Arginine Vasopressin in Advanced Vasodilatory Shock, A Prospective, Randomized Controlled Study,” Circulation, May 13, 2003, pp. 2313-2319.
Etter, E, et al., “Activation of Myosin Light Chain Phosphatase in Intact Arterial Smooth Muscle During Nitric Oxide-induced Relaxation,” The Journal of Biological Chemistry, Sep. 14, 2001, pp. 34681-34685, vol. 276, No. 37.
Evans, N., et al., “Inhibition by calyculin A and okadaic acid of the Ca2+ release-activated Ca2+ entry pathway in rat basophilic leukemia cells: Evidence for regulation by Type 1/2A serine/threonine phosphatase activity,” Biochimica et Biophysica Acta, 2005, pp. 32-43, 1718.
Fukao, M., et al., “Cyclic GMP-dependent Protein Kinase Activities Cloned BKCa Channels Expressed in Mammalian Cells by Direct Phosphorylation of Serine 1072,” The Journal of Biological Chemistry, Apr. 16, 1999, pp. 10927-10935, vol. 274, No. 16.
Hollenberg, S., et al., “Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats,” Am. J. Physiol., 1993, pp. H.660-H663, vol. 264.
Ishihara, H., et al., “Calcium-independent Activation of Contractile Apparatus in Smooth Muscle by Calyculin-A1,” The Journal of Pharmacology and Experimental Therapeutics, Apr. 10, 1989, pp. 388-396, vol. 250, No. 1.
Jaggar, J., et al., “Calcium sparks in smooth muscle,” Am. J. Physiol Cell Physiol, 2000, pp. 233-256, vol. 278.
Karim, S., et al., “Vascular Reactivity in Heart Failure,” Circ. Res., 2004, pp. 612-618, vol. 95.
Kato, Y., et al., “Calyculins, Potent Antitumour Metabolites From the Marine Sponge Discodermia Calyx: Biological Activities,” Drugs Exptl. Clin. Res., 1988, pp. 723-728, XIV(12).
Kilbourn, R., “Nitric oxide synthase inhibitors—A mechanism-based treatment of septic shock,” Crit. Care Med., 1999, pp. 857-858, vol. 27, No. 5.
Leone, M., et al., “Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions,” Crit. Care Med., 2006, pp. 1126-1130, vol. 34, No. 4.
Lincoln, T., et al., “Signal Transduction in Smooth Muscle Invited Review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression,” J. Appl. Physiol., 2001, pp. 1421-1430, vol. 91.
Murphy, M., et al., “Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels,” The Journal of Physiology, 1995, pp. 47-58, vol. 486.
Parekh, A., et al., “Depletion of InsP3 stores activates a Ca2+ and K+ current by means of a phosphatase and a diffusible messenger,” Nature, Aug. 26, 1993, pp. 814-818, vol. 364.
Quayle, J., et al., “ATP-Sensitive and Inwardly Rectifying Potassium Channels in Smooth Muscle,” Physiological Reviews, Oct. 1997, pp. 1165-1232, vol. 77, No. 4.
Schmidt, H., et al., “The nitric oxide and cGMP signal transduction system: regulation and mechanism of action,” Biochimica et Biophysica Acta, 1993, pp. 153-175, vol. 1178.
Somlyo, A., et al., “Ca2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase,” Physiol. Rev., 2003, pp. 1325-1358, vol. 83.
Surks, H., et al., “Regulation of Myosin Phosphatase by a Specific Interaction with cGMP-Dependent Protein Kinase 1α,” Science, Nov. 19, 1999, pp. 1583-1587, vol. 286.
Webb, R., “Smooth Muscle Contraction and Relaxation,” Adv. Physiol. Educ., 2003, pp. 201-206, vol. 27.
Yano, Y., et al., “Cytoskeletal reorganization of human platelets inducted by the protein phosphatase 1/2A inhibitors okadaic acid and calyculin A,” Biochem J., 1995, pp. 439-449, vol. 307.
Ballard Kimberly A.
Kemmerer Elizabeth C.
Polsinelli Shughart PC
Washington University
LandOfFree
Methods of treating vasodilatory shock does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating vasodilatory shock, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating vasodilatory shock will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154310